[ Neoton and thrombolytic therapy of <font color="blue">myocardial_3</font> <font color="blue">infarction_3</font> <font color="blue">]_3</font> . 
<br>
<br> AIM To evaluate neoton therapy <font color="blue">effects_1</font> <font color="blue">in_1</font> <font color="blue">acute_2</font> <font color="blue">myocardial_2</font> <font color="blue">infarction_2</font> <font color="blue">(_2</font> <font color="blue">MI_2</font> <font color="blue">)_2</font> <font color="blue">on_2</font> <font color="blue">systolic_2</font> <font color="blue">function_2</font> <font color="blue">of_2</font> <font color="blue">the_2</font> <font color="blue">left_2</font> <font color="blue">ventricle_2</font> <font color="blue">,_2</font> <font color="blue">arrhythmia_2</font> <font color="blue">and_2</font> <font color="blue">clinical_2</font> <font color="blue">symptoms_2</font> <font color="blue">in_2</font> <font color="blue">patients_6</font> <font color="blue">on_5</font> <font color="blue">thrombolytic_5</font> <font color="blue">therapy_5</font> <font color="blue">(_5</font> <font color="blue">TLT_5</font> <font color="blue">)_5</font> <font color="blue">._5</font> <font color="blue">
<br>_3</font> MATERIAL AND METHODS <font color="blue">106_5</font> <font color="blue">males_5</font> <font color="blue">with_5</font> <font color="blue">Q_5</font> <font color="blue">-_5</font> <font color="blue">MI_5</font> <font color="blue">entered_2</font> <font color="blue">the_2</font> <font color="blue">study_2</font> <font color="blue">._2</font> <font color="blue">47_1</font> <font color="blue">received_1</font> <font color="blue">treatment_1</font> <font color="blue">without_1</font> <font color="blue">TLT_1</font> <font color="blue">and_1</font> <font color="blue">neoton_1</font> <font color="blue">,_1</font> <font color="blue">30_1</font> <font color="blue">patients_1</font> <font color="blue">received_1</font> <font color="blue">TLT_1</font> <font color="blue">with_1</font> <font color="blue">streptokinase_1</font> <font color="blue">preparations_1</font> <font color="blue">,_1</font> <font color="blue">29_1</font> <font color="blue">patients_1</font> were given streptokinase preparations and neoton . Left ventricular systolic function was measured by echocardiography on day 1 , 3 , 7 , 14 , 21 and 28 ; arrhythmia was analysed at Holter monitoring in day 1 and 2 of MI . 
<br> RESULTS TLT failed to arrest progression of left ventricular dilation by the end of the hospital stay . Patients given neoton in acute period of MI had no increase in the end systolic and diastolic volumes of the left ventricle in the course of the first months after MI onset . Antiarrhythmic action of neoton manifested on MI day 2 . 
<br> CONCLUSION Neoton given to <font color="blue">MI_1</font> <font color="blue">patients_1</font> receiving TLT prevents progression of left ventricular systolic dysfunction and establishment of predictors of unfavourable outcome .